Latest research on Olmesartan medoxomil

Olmesartan is an antihypertensive agent, which belongs to the class of medications called angiotensin II receptor blockers. It is indicated for the treatment of high blood pressure and is marketed under the name Olmetec®. The FDA label includes a black-box warning of injury and death to the fetus, so women of child-bearing age need to be warned and take the necessary precautions. Olmesartan is also contraindicated in diabetes mellitus patients taking aliskiren.

Olmesartan medoxomil interactions

The availability of a large database of elderly hypertensive patients enrolled in two randomized, double-blind, parallel group studies with a similar design, comparing the efficacy of an angiotensin-receptor blocker (ARB), Olmesartan medoxomil, with that of the angiotensin-converting enzyme (ACE)-inhibitor, Ramipril, gave us the possibility to explore such a scenario. [source, 2015]
Briefly, the two Original studies18,19 had a multicenter, randomized, double-blind, parallel group design, consisting of a 2-week washout with placebo, followed by 12 weeks of treatment with Olmesartan medoxomil or Ramipril at initial doses of 10 or 2.5 mg once daily, respectively. [source, 2015]
Despite the potential advantage of Amlodipine orotate, no bioequivalence studies on the combination of Amlodipine orotate and Olmesartan medoxomil have been published. [source, 2015]
In the last step, the trityl protection group was removed by treating the Trityl Olmesartan medoxomil with Acetic Acid. [source, 2015]
The sorption of 0.9% solution of Griseofulvin in PEG 300 [35] and Olmesartan medoxomil in Acrysol EL 135 [36] onto carrier Neusilin US2 are two examples of this. [source, 2015]
In a sub-analysis of the TRINITY trial (Triple therapy with Olmesartan medoxomil, Amlodipine, and Hydrochlorothiazide in hypertensive patients; number, NCT00649389) the effect of triple combination therapy was assessed, with doses up to 40 mg of olmesartan, 10 mg of Amlodipine, and 25 mg of Hydrochlorothiazide, using ABPM in 440 patients with HTN defined as moderate to severe based on a systolic BP ≥160 mmHg or a diastolic BP ≥100 mmHg. [source, 2015]
Here, we investigated the effects of the AT1 receptor blocker Olmesartan medoxomil and the calcium channel antagonist Amlodipine besylate on atherosclerotic progression and vascular inflammation using an ApoE−/− mouse model of advanced atherosclerosis. [source, 2015]
Mice were randomized into four groups and were fed a chow supplemented with Olmesartan medoxomil (1 mg/kg/day; n=15), Amlodipine besylate (1.5 mg/kg/day; n=15), or their combination (n=17). [source, 2015]
We chose the dose of Olmesartan medoxomil and Amlodipine besylate in accordance with a study of Suzuki et al13 and Yoshii et al14 in which the authors demonstrated significant antiatherosclerotic properties of a single treatment with Olmesartan medoxomil or Amlodipine besylate without affecting systolic blood pressure. [source, 2015]
Morphometric analysis of Movat’s pentachrome staining revealed a markedly significant reduction of atherosclerotic lesion size in the group receiving the combination of Olmesartan medoxomil and Amlodipine besylate after 25 weeks on the study diet. [source, 2015]